Fibrocell Science — Investor Presentation (July 2015)
20 slides from Fibrocell Science's investor presentation, Jul 21, 2015
Slide 1: Fibrocell Corporate Presentation
Fibrocell Corporate Presentation 21 July 2015 1
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation contains, and our officers and representatives may from time to time make, statements that are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of forwar
Slide 3: Company Highlights
• Fibrocell is the leader of autologous fibroblast therapy for skin and connective tissue diseases – Developing a pipeline of cell and gene therapies for orphan skin diseases using autologous fibroblasts to deliver a targeted gene • Phase II azficel-T sBLA program: autologous fibroblasts for Chronic
Slide 4: Autologous Fibroblasts as a Therapy
Autologous Fibroblasts as a Therapy • Fibroblasts repair tissue infrastructure by producing extracellular matrix proteins including collagen and growth factors • Most common cell in skin and connective tissue • Key advantages of our autologous fibroblast/gene-therapy approach: ‐ Monogenic (one gene)
Slide 5: Two Product Engines – Multiple Therapeutics in Development
Gene Therapy Product Engine integrates Intrexon’s synthetic biology FCX-007, FCX-013 Autologous Fibroblast Product Engine azficel-T BLA* Two Product Engines – Multiple Therapeutics in Development Collection Culture Local Administration Vector Preparation Gene Packaging Gene Transduction Personalized
Slide 6: Development Pipeline
Personalized Biologics Indication Pre-Clinical Development Phase 1 Phase 2 Phase 3 azficel-T sBLA* Chronic Dysphonia FCX-007 Gene-Therapy Orphan Drug Candidate Recessive Dystrophic Epidermolysis Bullosa (RDEB) FCX-013 Gene-Therapy Potential Orphan Drug Candidate Linear Scleroderma Development Pipeli
Slide 7: Chronic Dysphonia
Disease Current Treatments Epidemiology Damage to the fibroblast layer causes scarring and edema which limits air flow and results in severe and significant limitations in voice quality, often loss of voice • Current treatments only address symptoms • Voice therapy • Surgery - Injection (collagen, f
Slide 8: Clinical Data Support Our Approach in Chronic Dysphonia
Positive Phase I clinical trial results published in peer-reviewed journal2 • Injection of azficel-T into scarred fold lamina propria layer was found to be safe and well-tolerated in trial (n=5) ₋ All patients completed the trial ₋ No serious adverse events reported • Positive trend of sustained imp
Slide 9: Chronic Dysphonia Phase II
• Fully enrolled 20+ subjects • Double-blind, randomized, placebo-controlled • Validated scales with a 4-month efficacy endpoint • Dosing expected to be complete by year-end 2015 • Expect to report primary endpoint results in 2Q16 Chronic Dysphonia Phase II 9
Slide 10: Providing Hope for RDEB Patients
Providing Hope for RDEB Patients 10 RDEB patients do not produce type VII collagen (COL7) due to mutation in COL7A1 gene ‐ Main component of anchoring fibrils that connect skin layers FCX-007 is an autologous human dermal fibroblast transduced with a vector containing the gene for COL7A1 ‐ Simple, l
Slide 11: Recessive Dystrophic Epidermolysis Bullosa
Disease Current Treatments Epidemiology • Devastating, progressive, painful blistering disease that leads to death • Diagnosed at infancy • High mortality rate • Cause: A mutation in the COL7A1 gene which encodes for COL7 • Current treatments only address symptoms • Bandaging & antibiotics – bandagi
Slide 12: FCX-007: Rapid Regulatory Progression to IND
FCX-007: Rapid Regulatory Progression to IND 12 2Q2014 • Granted Orphan Status for DEB by FDA (June 2014) 3Q2014 • Held Pre-IND Meeting with FDA (August 2014) 4Q1014 1Q2015 • Clinical Trial Protocol Cleared by NIH Recombinant DNA Advisory Committee (Feb 2015) 2Q2015 • Granted Rare Pediatric Disease
Slide 13: COL7 Expression Confirmation
COL7 Expression Confirmation COL7 Trimer COL7 FORMATION 290kDa ~900kDa Culture supernatant evaluated for COL7 expression: • ELISA assay indicates virus dose-dependent protein expression • Trimeric form of COL7 produced by RDEB patient fibroblasts transduced with LV-COL7 ~ 900kDa 13
Slide 14: In Vitro Results Summary
In Vitro Results Summary 14 Study Results: Results Suggest: Production of LV-COL7 was demonstrated Ability to successfully make the vector FCX-007 was produced by expanding LV-COL7-transduced RDEB patient fibroblasts from a biopsy sample Ability for full-scale FCX-007 production The integrated trans
Slide 15: Positive Pre-Clinical Results
Positive Pre-Clinical Results Toxicity • SCID mice grafted with normal human skin graft & injected with FCX-007 to determine toxicity and systemic distribution of vector • Results: – No adverse observations at 2 and 6 weeks post-injection – No apparent vector distribution based on qPCR of organ samp
Slide 16: FCX-007 Proposed Clinical Trial Design
FCX-007 Proposed Clinical Trial Design Title A Phase I/II Trial of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Statement of Purpose The purpose of this study is threefold: 1) To evaluate the safety of FCX-007 2) To evaluate
Slide 17: Linear Scleroderma
Disease Epidemiology • Excess production of extracellular matrix characterized by skin fibrosis and linear scars • The linear areas of skin thickening may extend to underlying tissue and muscle in children which may impair growth in affected legs and arms or forehead • Lesions appearing across joint
Slide 18: FCX-013 Development Progressing
• Preliminary protein expression levels determined • Product Profile – Genetically-modified autologous dermal fibroblasts – Gene construct identified, target gene selected – Preparing scale-up manufacturing using lentivirus • Animal model candidate in development • Anticipated milestones – Proof-of-
Slide 19: Anticipated Milestones
Anticipated Milestones 19 Anticipated Milestones Timing FCX-007 IND Submitted (17 July 2015) Complete FCX-007 Phase I Initiation 2H15 azficel-T sBLA Phase II Data 2Q16 FCX-013 Proof-of-Concept Data 1H16 FCX-013 IND Submission 4Q16
Slide 20: References
References 1Data on file. Fibrocell Science, Inc. 2Chhetri, Dinesh, Injection of Cultured Autologous Fibroblasts for Human Vocal Fold Scars. The Laryngoscope 121(4):785-792, 2011. 3 The Dystrophic Epidermolysis Research Association of America (DebRA). DEB brochure, page 6: http://www.debra.org/pdfs/
Fibrocell Science — Investor Presentation (July 2015) on 6ix